Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RBX 2660

Next Previous
Drug Profile

RBX 2660

Alternative Names: Faecal microbiota transplant - Rebiotix; fecal microbiota, live – jslm; Microbiota restoration therapy; Microbiota suspension; RBX-2660; REBYOTA

Latest Information Update: 05 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Rebiotix
  • Developer McMaster Childrens Hospital; Rebiotix; University of Alberta
  • Class Anti-inflammatories; Bacteria; Urinary anti-infective agents
  • Mechanism of Action Bacteria replacements; Gastrointestinal microbiome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Clostridium infections
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Clostridium difficile infections
  • Phase I/II Hepatic encephalopathy; Urinary tract infections
  • No development reported Crohn's disease; Ulcerative colitis; Vancomycin-resistant enterococcal infections

Most Recent Events

  • 05 Nov 2025 RBX 2660 is available for licensing as of 30 Oct 2025. https://www.ferring.com/ferring-pharmaceuticals-to-explore-strategic-options-for-rebyota/
  • 27 Oct 2025 Efficacy and adverse event data from the phase III trial in Clostridium difficile infections released by Ferring Pharmaceuticals
  • 05 May 2025 Efficacy and adverse event data from the phase III CDI-SCOPE trial in Clostridium difficile infections released by Ferring Pharmaceuticals

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top